Product Name:3,6-dichloro-4-methylpyridazine

IUPAC Name:3,6-dichloro-4-methylpyridazine

CAS:19064-64-3
Molecular Formula:C5H4Cl2N2
Purity:97%
Catalog Number:CM102253
Molecular Weight:163

Packing Unit Available Stock Price($) Quantity
CM102253-100g in stock șź
CM102253-500g in stock ȀŔș

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:19064-64-3
Molecular Formula:C5H4Cl2N2
Melting Point:-
Smiles Code:CC1=CC(Cl)=NN=C1Cl
Density:
Catalog Number:CM102253
Molecular Weight:163
Boiling Point:272.1°C
MDL No:MFCD00006465
Storage:Store at 2-8°C.

Category Infos

Pyridazines
Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

Column Infos

Risdiplam
As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.